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j Abstract A systematic review of
published and unpublished data
on the use of long-acting medica-
tions in ADHD and hyperkinetic
disorder is reported, giving effect
sizes and numbers-to-treat for
extended-release stimulant prepa-
rations and atomoxetine (ATX). A
panel of experts from several
European countries used the re-
view to make recommendations
about the use of these drugs in
practice, and conclusions are re-
ported: (1) Long-acting prepara-
tions should be available and used;
(2) They should not replace short-
acting drugs (which will be the
initial treatment for many children
for reasons of cost and flexibility
of dosing). Individual clinical
choice is needed. (3) Both ATX
and extended-release preparations
of stimulants should be available.
The choice will depend upon the
circumstances, and detailed rec-
ommendations are made.
j Key words guidelines –
review – stimulants –
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Introduction
j Background
A group of European physicians and psychologists
recently published guidelines for the treatment of
hyperkinetic disorders [71]. There have been several
developments in the field since then; one has been the
advent of newly licensed drugs and drug preparations
whose effect lasts through a substantial part of the
day. This can overcome the inconveniences of the
short-acting stimulants. A non-stimulant has been
licensed, and often is in use. All, however, entail in-
creased costs, and the choice among them can be
confusing. This paper provides a review of their use.
The previous guidelines for the treatment of
hyperkinetic disorders are still valid: a comprehensive
treatment programme should include measures other
than medicines—such as psychological, educational
and social interventions. Treatment should be initi-
ated under the supervision of a specialist in childhood
behavioural disorders. Diagnosis should be made in
accordance with DSM-IV criteria or the guidelines in
ICD-10 and should be based on a full history and
evaluation of the patient. Pharmacotherapy is not
indicated for all children with this syndrome and the
decision to use any of the drugs must be based on a
thorough assessment of the severity, impact and
developmental appropriateness of the child’s symp-
toms. The current paper should be seen as a supple-
ment to these recommendations.
j Methodology of the review and guideline
development
A group of experienced academic clinicians and
clinical researchers with special interests in the
hyperkinetic disorders was identified through the
European Network for Hyperkinetic Disorders
(EUNETHYDIS). Systematic reviews by NICE [30]
and SIGN [54] were recent and available, and formed
the basis for identifying published papers on meth-
ylphenidate, dexamfetamine and atomoxetine (ATX).
Faraone’s meta-analyses [12, 14, 15] were also re-
ferred to. Pharmaceutical companies with long-acting
drugs in their portfolios were asked to provide
unpublished as well as published data and posters
(but information in commercial confidence was not
included). The companies also presented at a meeting
in September 2005 held in London. The calculation of
effect sizes was carried out using a standard meth-
odology. Where companies provided calculations of
effect sizes using the standard methodology these
were employed. If companies did not provide calcu-
lations using the standard methodology they were
calculated by the authors.
The review and guideline development process was
iterative. The identification of clinical questions was
carried out in a meeting of all the authors, and a
working group (TB, DC, SP, AZ) made a systematic
review of published and unpublished clinical trials
incorporating long-acting preparations; a quantitative
review of the relevant data is reported below. Further
meetings critiqued these reviews and their conclu-
sions. A quantitative methodology for resolving dis-
agreements had been anticipated (including an
assessment of competing-interest information); but in
the event, conclusions were unanimous. Drafts of the
paper were exchanged and discussed iteratively. The
final document is subscribed to by all the authors. The
paper includes both a narrative summary of conclu-
sions and a scientific examination of the data in two
separate sections.
Narrative review and recommendations
j Description of the drugs
Stimulants
j Methylphenidate hydrochloride
Methylphenidate hydrochloride (MPH) is a mild
central nervous system (CNS) stimulant with more
prominent effects on mental than motor activities. Its
use in the treatment of hyperkinetic disorder and
other forms of ADHD is well established and has been
reviewed by EUNETHYDIS for European Child and
Adolescent Psychiatry [71]. It is licensed in most
European countries as part of comprehensive treat-
ment programmes in children (over 6) and adoles-
cents when remedial measures alone prove
insufficient. Ritalin LA (Novartis), Equasym XL
(UCB), Concerta XL (Janssen–Cilag) and Medikinet
Retard (Medice) all provide a mixture of immediate-
and extended-release methylphenidate; they differ in
the physics of the delayed-release system and in the
proportion of immediate to delayed. Figure 1 shows
the pharmacokinetic (PK) profile over time of these
different formulations; the actions on behaviour
parallel the concentrations in the blood.
j Concerta XL
Pharmacology: Concerta XL employs an osmotic
pump system (OROS), which has been designed to
have a12-h duration of effect. An 18 mg tablet in-
cludes a shell of 4 mg immediate-release (i.e. 22%). In
clinical trials, Concerta XL has been shown to be as
effective as 3-times-a-day methylphenidate [48, 80].
However, a 20% higher dose of Concerta XL was re-
quired in the Pelham et al. [48] study.
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Time course of action: After oral administration of
Concerta XL to adults, plasma methylphenidate con-
centrations rise and reach an initial maximum after
1–2 h, due to the capsule drug overcoat dissolving.
Following this, the concentrations increase gradually,
due to slow release from the capsule functioning as an
osmotic pump designed to deliver MPH with an
ascending profile for about 10 h after administration
[69]. The action on behaviour is stated to last about
12 h [69]; but clinical experience suggests that (as
with other ER preparations) there is considerable
inter-individual variation.
Clinical aspects: Concerta XL is usually available in
18, 36 and 54 mg strengths. The tablets are adminis-
tered orally once daily in the morning, must be
swallowed whole with the aid of liquids, and must not
be chewed, divided or crushed. Concerta XL may be
administered with or without food. Dosage should be
individualised according to the needs and responses
of the patient, often by starting with 18 mg and
adjusting in 18 mg increments at approximately
weekly intervals. The maximum dose is stated as
54 mg; but this takes no account of the patient’s size
and the guidelines group consider higher doses up to
% IR % ER % IR % ER MPH IR BID
100%  
CONCERTA XL 
22% 78% 
EQUASYM XL
30% 70% 
MEDIKINET RETARD
50% 50% 
RITALIN LA 
50% 50% 
ADDERALL XR 
50% 50% 
Fig. 1 MPH and amphetamine plasma levels over time with different
preparations and their IR/ER proportions Note: curves for MPH IR BID,
Medikinet retard provided by Medice, for Adderall XR provided by Shire; for
Ritalin LA see: Markowitz et al. [39]; for Concerta XL and Equasym XL see:
Gonzalez et al. [21]; all curves are adapted to a common time-scale. Doses of
different products are not equivalent so there is no common Y-axis and direct
comparisons should not be made for the absolute levels
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a maximum of 2 mg/kg/day; or 108 mg total daily
dose—whichever is the smaller, to be acceptable and
recommended in some cases. It is possible to titrate
children straight on to Concerta XL without their
needing to be first titrated on to immediate-release
stimulant medication [68]. Some clinicians, however,
prefer to establish the optimal dose by first titrating
with immediate-release.
j Equasym XL
Pharmacology: In Equasym XL, the capsules comprise
both immediate- and extended-release beads such
that 30% of the dose is provided by the immediate
release component and 70% of the dose is provided
by the extended-release component.
Time course of action: In line with its different
dosing profiles, Equasym XL has a shorter duration of
action than Concerta XL (approximately 8 h) but a
larger effect in the 4–5 h immediately after dosing
given similar total daily doses [70]. As with Concerta
XL there is variation between individuals in the time
course of action.
Clinical aspects: At the time of writing, Equasym
XL is only available in the UK. The drug is
administered once daily in the morning, before
breakfast. Our recommended starting dose is 10 mg
once daily. The company’s advice is that dosage
may be adjusted in weekly 20 mg increments to a
maximum of 60 mg/day; our experience is in line
with this, but there may be a limited number of
cases who benefit from higher doses and the max-
imum for them is 2 mg/kg/day; or 100 mg total
daily dose—whichever is the smaller.
j Medikinet retard
Pharmacology: This is another proprietary formula-
tion of methylphenidate, made in Germany and li-
censed only there at the time of writing, mixing 50%
immediate with 50% extended, coated for gastric acid
resistance.
Time course of action: The effective action is at
least 7 h and the effects of once daily Medikinet Re-
tard are comparable to the effects of twice daily Rit-
alin [11]. As with Equasym XL the dosing profile
predicts a larger immediate, and smaller delayed,
action than Concerta XL, with individual differences
in time course being observed.
Clinical aspects: The drug is administered once
daily in the morning, after breakfast. If titration is
done with this drug our recommended starting dose
is 10 mg once daily. The company’s advice is that
dosage may be adjusted in weekly 10 mg incre-
ments. The maximum dose is as for Equasym XL
(above).
j Ritalin LA
Pharmacology: Ritalin LA includes a mixture of
immediate- and extended-release beads using the
proprietary SODAS (Spheroidal Oral Drug Absorption
System) drug delivery system. It has about 50–50
proportions of immediate and delayed release. It is
licensed in a small number of European countries as
well as the USA.
Time course of action: As with Equasym XL and
Medikinet Retard the dosing profile predicts a larger
immediate, and smaller delayed, action than Concerta
XL and some evidence supports this [36].
Clinical aspects: Recommended doses are as for
Equasym XL.
One characteristic of Ritalin LA, Medikinet Retard
and Equasym XL, is that the capsules can be opened
and the contents sprinkled on a suitable foodstuff
without any loss of activity. In most cases, formula-
tions are not licensed for this use and this practice is
not recommended by the manufacturers. However,
‘sprinkling’ can be useful for children who have dif-
ficulties swallowing. It has also been suggested that
given this characteristic these formulations could be
easier to abuse, although there is no evidence for this
view.
j Adderall XR
Pharmacology: Adderall XR, like its IR predecessor
Adderall, is composed of four amphetamine salts:
amphetamine aspartate, amphetamine sulfate, dex-
amfetamine1 saccharate, and dextroamfetamine sul-
fate (this last is the active ingredient of Dexedrine).
These four component salts are metabolised at dif-
ferent rates. Adderall XR utilises a beaded delivery
system in which the first type of bead dissolves
immediately and the second type 4 h later. The drug
is not licensed in Europe, but clinicians may
encounter it in immigrants already using it.
Time course of action: Maximum plasma concen-
tration is achieved in 7 h, compared to regular Ad-
derall IR (immediate-release) that reaches maximum
plasma concentration within 3 h. The duration of
action is around 8–10 h [42].
Clinical aspects: Doses for both immediate- and
extended-release form come in 5, 10, 15, 20, 25, and
30 mg increments.
1The spelling of dexamfetamine reflects the changes made in
‘Recommended International Non-proprietary Names’ (rINN) and
‘New British Approved Names’ (BAN) and follow European
Directive 92/27/EEC. ‘‘Amphetamine’’ has not yet followed the
convention. We are therefore following this inconsistent rule of
spelling to help people using electronic retrieval. Trade rather than
generic names of drugs have been used to distinguish the different
preparations conveniently.
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Two other extended-release stimulants, Ritalin-SR
and Focalin XR (dexmethylphenidate extended re-
lease) will not be covered in this review. Ritalin-SR is
likely to be replaced in the market by the more clin-
ically effective Ritalin LA. Focalin XR is currently not
available in Europe.
Adverse effects and misuse of stimulants
All stimulants, whether immediate- or extended-re-
lease, share some disadvantages. They can be both
abused by the patient and diverted to an illegal rec-
reational market. They, therefore, represent a poten-
tial public health risk. They are sometimes ineffective.
The adverse effects (insomnia, appetite loss, growth
retardation, abdominal pain, and occasionally dys-
phoria, tics or agitation) can sometimes be unac-
ceptable. The issue of long-term growth retardation
has received much attention recently but the issue is
complex and current data are conflicting [70, 78] and
do not allow the effects to be determined definitively.
Nevertheless, the group recommend that children’s
height and weight should be monitored as a matter of
course and followed on growth charts. Stimulants are
contraindicated in several circumstances, most of
them uncommon in childhood: schizophrenia, severe
depression, hyperthyroidism, cardiac arrhythmias,
moderate to severe hypertension, angina pectoris,
glaucoma, previous hypersensitivity, or concomitant
use—or use within the last 2 weeks—of monoamine
oxidase (MAO) inhibitors. Caution is advised in: pa-
tients with motor tics, patients with known drug
dependence or history of drug dependence or alco-
holism, pregnancy and breast-feeding, anorexia
nervosa, or a history of suicidal tendency. People with
pre-existing cardiac abnormalities may be at special
risk. Strategies for dealing with side effects include
monitoring, dose adjustment of the stimulant,
switching medication, and adjunctive pharmacother-
apy to treat the side effects (see [71]).
Stimulants were introduced at a time when drug
hazards were less rigorously monitored than is now
the case. Strattera has been developed under stricter
surveillance, and as a result some uncommon adverse
events have been notified to regulatory authorities (see
below). This in turn has led to a need to reconsider the
possibility that stimulants too could have relation-
ships with cardiac arrhythmias, liver failure, suicidal
thoughts and seizures. For example, an unpublished
report provided to a panel of the (US) Food and Drug
Administration described seven reported cases of
sudden death in children taking methylphenidate,
relative to about 10 million prescriptions. In present
knowledge, we think it is unlikely that this is greater
than the rate in the untreated population, but also that
the true figures of adverse reactions are probably
greater than reported. The main practical implications
are to include physical examination before prescrip-
tion—to seek for cardiovascular abnormalities such as
raised blood pressure or heart murmurs (ECG is op-
tional) and enquire about symptoms such as syncope
on exercise, with cardiological evaluation if a warning
sign is found; and to include enquiry about seizures,
signs of liver damage, or heart irregularities in moni-
toring patients. These recommendations are the same
as those for immediate-release drugs, and do not differ
for different stimulants or preparations. Routine blood
tests are not recommended by us (though they are by
the companies); blood dyscrasias can occur as a rare
event, as with most medicines, but there is no sug-
gestion either that the risk is big enough to justify
monitoring or that it could be detected by infrequent
tests.
Stimulants are controlled substances. Nevertheless,
a meta-analysis of long-term naturalistic studies of
stimulant treatment in ADHD concluded that stimu-
lant treatment does not increase the risk of substance
abuse [79].
Limited information is available regarding the
inappropriate use of stimulants in patients with
ADHD. Data on different forms of misuse (e.g., for
cognitive enhancement by healthy people) and
diversion of stimulants are few. Recently, Wilens et al.
[77] evaluated the prevalence and correlates of stim-
ulant diversion and inappropriate use in young North
American adults with ADHD using a self-report
questionnaire. It was based on a relatively small cross-
sectional sample. They found, rather alarmingly, that
out of 98 subjects with ADHD who were taking
medication, 11% said that they had sold their pre-
scribed medication, and 22% had ‘‘misused’’ medi-
cation in the sense of escalating dose without proper
authorisation.
The 2004 US National Survey on Drug Use and
Health also found evidence that a minority of patients
may sell or misuse the medication [53] and a survey
of 10,904 randomly selected college students in the US
found that the life-time prevalence of non-medical
prescription stimulant use was 6.9% [41]. Data for
Europe are lacking. Little evidence was found of
misuse/diversion in subjects with ADHD who did not
already have substance abuse or conduct problems.
All of the medications misused/diverted were imme-
diate-release preparations of stimulants, suggesting
that extended-release stimulants are less likely to be
used inappropriately or diverted. This in turn sug-
gests that IR formulations of MPH should not be
prescribed in drug abusers and high-risk populations
as first choice.
In some European countries, the perceived risk of
drug abuse has led to stimulants being forbidden on
public health grounds. We considered that this is a
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disproportionate response, causing disadvantage to
patients without likely impact on rates of substance
abuse.
Non-stimulants
j Atomoxetine hydrochloride—Strattera
Pharmacology: ATX, brand name Strattera, is a
selective noradrenaline transporter blocker. It is
currently licensed in several countries for the treat-
ment of ADHD in children over six and adolescents
and adults who were treated as adolescents. It is
metabolised by the cytochrome enzyme P450 2D6;
people with low levels of activity of this enzyme me-
tabolise the drug more slowly and may well need
lower doses. Drugs inhibiting P450 2D6 (such as flu-
oxetine)2 will lead to higher blood levels of Strattera
and may call for dosage adjustment.
Time course of action: The full effect of the medi-
cation appears only after 6–8 weeks of treatment or
longer; but responders usually show some change by
the 4-week point. Once full clinical effectiveness is
established this appears to persist across the day at a
fairly consistent level.
Clinical aspects: Like the stimulants, Strattera is
indicated as an integral part of a multimodal treat-
ment programme for patients with ADHD. Strattera is
available in 10, 18, 25, 40, or 60 mg capsules (for oral
administration with or without food). In children and
adolescents up to 70 kg in body weight, Strattera
should be initiated at a total daily dose of approxi-
mately 0.5 mg/kg and increased after a minimum of
7 days to a target daily dose of approximately 1.2 mg/
kg administered either as a single daily dose in the
morning or as evenly divided doses in the morning
and late afternoon/early evening. However, a single
evening administration produces lower efficacy and
less side effects [26]. The total daily dose in children
and adolescents should not exceed 1.8 mg/kg or
100 mg, whichever is less.
j Modanil—Provigil
Pharmacology: This is a chemically distinct drug,
established for the promotion of wakefulness, with
non-dopaminergic activating action on frontal cortex.
Time course of action: The effect is apparent from
about 1 week of therapy.
Tablets are 100 mg. The dose is around 350 mg
daily for children up to the age of 12.
Clinical aspects: Modafinil does not (at the time of
writing) have a marketing license for ADHD. The
guidelines group does not have sufficient experience
with it to make detailed recommendation, but it could
potentially be considered for children refractory to
other therapies.
Adverse effects of non-stimulants
A direct comparison of the adverse effects of Strattera
and extended-release stimulants is not really possible
on the basis of published data because Strattera has
been introduced at a time of closer regulation and
more explicit reporting; while stimulants have been
used for much longer period with correspondingly
greater chance of rare hazards appearing. For Strat-
tera common adverse effects include nausea, sedation
and appetite loss; other side effects of Strattera in-
clude dry mouth, insomnia, constipation, and mood
swings. Additionally, urinary retention and sexual
dysfunction have been observed in adult patients.
Most of these adverse effects diminish over the first
months of treatment. There is no significant differ-
ence in adverse events between normal and poor
metabolisers of Strattera.
Regulatory agencies, such as the MHRA (Medicines
and Health Care Products Regulatory Agency) in the
UK, collect spontaneous reports about problems that
have arisen in people treated with drugs. It can,
however, be hard to know whether such problems
would have arisen even if the drug had not been gi-
ven. The most common serious events reported have
been seizures: up to May 2005, there had been 212
recorded, from about 2.2 million treated, and the
figure is likely to underestimate the rate. Many,
however, were reported from people who were already
prone to seizures, or were taking other drugs that can
cause fits. The company reckoned that only 4 of the
212 events had no obvious cause other than Strattera,
and so it is not clear whether the drug can cause
seizures. We recommend caution: enquire about sei-
zures before prescribing, monitor seizure frequency
in those with epilepsy, and be alert to the possibility
of seizures appearing for the first time.
Suicidal ideation appears rarely—0.44% of people
treated in studies—but this is significantly more fre-
quent than in those given placebo (0%) [4], so pre-
scribers should be aware of this association and
prepared to detect depression and suicidality and to
treat, or refer, if necessary. Similar data for stimulants
are currently lacking. For Strattera, irritability, agi-
tation, anger or aggression may also occur in rare
cases.
The warnings given for serious idiosyncratic he-
patic events are similar to those for stimulants.
Strattera therapy should be discontinued in patients
2Useful websites with fuller information about these interactions
can be found at http://medicine.iupui.edu/flockhart/table.htm or at
http://www.medscape.com/druginfo/druginterchecker?src=ads
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who present with signs or symptoms of liver injury
such as jaundice, dark urine, or unexplained, persis-
tent ‘‘flu-like’’ symptoms, and these should be asked
about. Patients who develop symptoms of hepatic
disease should discontinue Strattera. Chemical mon-
itoring of hepatic function is, however, not recom-
mended [51]. Blood pressure can be increased and
should be monitored throughout therapy. The MHRA
has received reports of QT interval prolongation—not
enough to establish a link, but with particular concern
after overdose. We do not think that there is a need
for routine ECG monitoring, but recommend it for
people already known to have long QTc intervals (or a
family history), or who are also receiving drugs that
can also produce QT prolongation, or cause electro-
lyte disturbances, or inhibit cytochrome P450 2D6.
Unlike stimulants, preliminary data on Strattera do
not show any potential for abuse or long-term effects
on growth [64]. The following side effects have been
reported for Modafinil: insomnia, headache, nausea
and anorexia as common adverse effects; skin rashes,
including erythema multiforme and Steven-Johnson-
syndrome as less common ones. It is contraindicated
in hypertension and heart failure.
j Costs of medications
Table 1 indicates the current prices of drugs for all
available doses, based on those for the UK and
Germany. These data should be seen only as a
guide; the excess costs of extended-release over
immediate-release may be less when other factors
are taken into account, such as the costs of in-
school dosing for short-acting medications given in
school hours [38].
j Recommendations for use of long-acting
formulations
Should extended-release preparations be used?
The group was clear that there are benefits for at least
some children from preparations that can be given
once daily. They can be seen as superior to placebo
and some are equivalent to multiple doses of imme-
diate-release methylphenidate (see Part II for evi-
dence for this and other recommendations; the
guidelines group regard this as established at Grade A
according to the SIGN system given in Appendix 1).
The main countervailing argument is cost. This is
certainly a consideration for all publicly funded ser-
vices and some private practices. In reviewing the
published literature, NICE found little difference in
efficacy between multiple doses of immediate-release
methylphenidate and single doses of long-acting for-
mulations [30]. They also found no good evidence to
establish difference in efficacy between extended re-
lease methylphenidate formulations and Strattera in
terms of the reduction in core symptoms although
this view is challenged by recent meta-analysis, sup-
ported by our review below, showing a significantly
greater effect of stimulants [15]. This evidence should
not be considered conclusive given limitations in the
evidence base and dearth of well-designed head-to-
head trials. The relative cost-effectiveness of the
stimulants is, therefore, largely but not solely deter-
mined by the price of the drugs in the absence of good
data on other indicators such as those relating to
Quality of Life (QoL), while efficacy may become an
issue when non-stimulants are considered. In current
practice, dexamfetamine is substantially the least
expensive; but in our view this would not be preferred
Table 1 Indicative annual cost of licensed drugs (February 2006)
Generic Proprietary UK cost per tablet
per year (British National
Formulary)
Germanya cost per tablet
per year (Net wholesale
price including tax)
Methylphenidate hydrochloride Equasym 30 mgm/day = 273 € 30 mgm/daya = 390 €
Ritalin 30 mgm/day = 345 € 30 mgm/day = 577 €
Medikinet Not available 30 mgm/daya = 390 €
Concerta XL 36 mgm/day = 666 € 36 mgm/day = 1.072 €
Equasym XL 30 mgm/day = 867 € Not available
Medikinet retard Not available 30 mgm/day = 897 €
Dexamfetamine sulphate Dexedrine 15 mgm/day = 113 € Not available
Atomoxetine Strattera Once daily = 1.068 € Once dailyb = 1.286 €
Twice daily = 2.136 € Twice dailyc = 2.634)2695 €
Costs based on UK and German prices. Ritalin LA, which is not available in
either country, costs 447 € per tablet per year in Belgium
a German prices for Equasym and Medikinet are based upon 20 mg tablets, for
Ritalin on 10 mg tablets (20 mg not available). Corresponding prices for 10 mg
tablets Equasym or Medikinet are 514 €
b 40 or 60 mgm/day
c Depending on dose
NB prices vary from time to time, do not include costs of monitoring and
cotherapies, and are not the major decision in prescribing. The doses cited are
not necessarily equipotent
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over MPH because of its perceived presence in the
illegal drug scene and by the lack of good evidence on
safety (Good Practice). This aspect needs further
study. Excluding dexamfetamine, the next most cost-
effective is immediate-release methylphenidate. The
guidelines group recommend this as the drug of first
choice for the majority of patients when cost is a
consideration. The extra cost of extended-release is
hard to give precisely; it depends on pricing policies
in different countries that may change from time to
time. NICE economists attempted a calculation of the
cost for units of gain in the QoL of patients being
treated with Concerta XL, Equasym XL and Strattera
[30]. In general, the costs for available treatments fall
within the range that European society accepts in
medical treatment, and correspondingly all three
drugs types should be available in treatment regimes.
Calculations such as this do not give guidance for the
clinician in the individual case. For one thing, they are
heavily dependent upon very questionable estimates
about both the number of children who will fail to
comply with a regime and the changes achieved in
QoL measures.
Drugs with longer action have other advantages,
which may vary as a function of the administrative
context in different EU countries—especially, that
they do not have to be taken at school. The school
does not have the expense and risk of maintaining
good administration, and the child does not have the
potential stigma of being seen to take a pill. Compli-
ance may be correspondingly better, but data are few.
ADHD patients on long-acting preparations may be
more likely to persist on their medication than those
prescribed IR MPH and have significantly fewer
emergency room visits and general practitioner visits
per patient, on average, over 1 year [28, 34]. An
individual decision therefore needs to be made in the
light of the child’s circumstances. A little evidence
(Grade C) suggests that sustained release medications
may be less prone to abuse because they tend to have
a slower rate of onset of effect than IR medications
[73]. Kollins et al. [32] assessed the effects of sus-
tained-release methylphenidate (SR—equivalent to
extended release), immediate-release methylpheni-
date (IR), and placebo among ten healthy volunteers.
The IR medication produced increased ratings of
pleasant effects. In contrast, the SR formulation pro-
duced only transient effects. These results should be
taken with caution until good data emerge on abuse
potential. In summary, the guidelines group consider
the key advantages of immediate-release stimulants to
be its lower cost and flexibility of dosage; the key
advantages of long-acting drugs as a potential
reduction of stigma at school, and improved com-
pliance and possibly reduced risk of misuse. The
conclusions were therefore (1) that long-acting
preparations should be available and used; and (2)
that they should not entirely replace short-acting
drugs. Individual clinical choice will determine the
choice of formulation used.
Which long-acting drug to use?
The comparative merits of the long-acting prepara-
tions have been hotly disputed. Part 3 of this paper
provides a detailed review. Although between-study
comparisons of effect sizes are useful, they must be
considered cautiously because the trials being com-
pared differed not only in the type of active medication
employed but also in other design features that may
have affected the results (e.g., outcome measures,
raters, doses, experimental design). There are some
trial data based on direct comparisons of Concerta XL
and the other drugs. These include data against Equ-
asym XL [70] and Strattera [76]: The first highlighting
the different profile of effect across the day and the
second suggesting that Concerta XL had a significantly
larger effect. This latter trial did, however, exclude
children who previously had a poor response to
methylphenidate. This was for sound ethical rea-
sons—it would scarcely have been justifiable to
randomise them to a drug known not to help them. But
the effect could well have been to bias the comparison
in Concerta XL’s favour; and a subgroup analysis of
children who had not previously received stimulants
(the key group for clinicians choosing the first treat-
ment) yielded no significant differences between the
preparations. A recent comparison of Adderall XR and
Strattera suggested that the mixed amphetamine salts
of Adderall XR had, in the doses administered, the
larger effect on a hyperactivity rating scale [76]. In line
with meta-analysis [15], the review reported here
suggests that the effectiveness of Strattera is likely to
be somewhat less than that of stimulants generally, on
the basis of the data provided by the companies—but
the studies are heterogeneous in design, doses and
subjects treated. In terms of normalisation rates and
numbers needed to treat, differences are less obvious.
Qualitative as well as quantitative considerations,
therefore, come into the choice of a long-acting
preparation. For instance, Strattera can have an action
throughout the day and this may be welcome to fam-
ilies who may struggle in mornings and evenings [27].
It helps some children who are not helped by meth-
ylphenidate (and vice versa).
The balance of adverse effects is different for
stimulants and non-stimulants—Strattera is more
likely to produce somnolence, methylphenidate
insomnia; Strattera nausea, methylphenidate anorex-
ia. Strattera may, therefore, be particularly useful
when adverse effects have limited the value of a
stimulant. There is possibly a lower abuse potential
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for Concerta XL related to properties inherent in the
OROS technology compared to other MPH-ER for-
mulations (although further research is needed to test
this, see above)3 However, Strattera may be consid-
ered as a first choice in populations at risk. It does not
have a greater abuse potential than desipramine [24].
Both Strattera and extended-release preparations
of methylphenidate should be available. Adderall XR
has not been considered in detail in this guideline
because of its unlicensed status in Europe. The choice
will depend upon the circumstances:
If treatment is starting with a long-acting prepa-
ration, then considerations4 of the anticipated average
cost/dose and efficacy suggest starting with extended-
release methylphenidate and proceeding to Strattera
if the former is unhelpful (Grade B for comparative
effect). The choice of extended-release methylpheni-
date will depend upon the profile of action required
over time, and upon the availability of drug. Strattera
is a relatively expensive drug; so a cost-effective pol-
icy will usually reserve it for cases where methyl-
phenidate is unhelpful or contraindicated. It may
nevertheless be preferred as first choice if substance
abuse or comorbid tics are a problem, if there is a
strong family preference for a non-stimulant, or if a
24-h action is particularly strongly required [27].
If a child has responded well to immediate-release
methylphenidate, there may still be reasons to shift to
extended-release—for example, to avoid the stigma or
inconvenience of repeated dosing. Clearly, an ex-
tended-release preparation of methylphenidate will
then be preferred.
If a child has suffered adverse effects on immediate-
releasemethylphenidate, then the next stepwill often be
to proceed to Strattera (Grade B for difference in ad-
verse effect profile; see above). The previous ‘European
Guidelines’ paper outlines symptomatic actions to be
taken to limit the impact of adverse effects [71]. For
instance, growth effects are not sufficiently different
between drugs that one rather than another should
routinely be preferred on those grounds. But, if an
individual child’s growth is decelerating on stimulants
and cannot be managed conservatively then a switch to
Strattera is a rational move.
If a child has failed to respond to immediate-release
methylphenidate because of lack of efficacy rather
than adverse effect, then the next option to try either
immediate release dexamfetamine if available and
acceptable (see above and previous guidelines [71] or
Strattera). If dexamfetamine fails, or is unacceptable
or unavailable, or if the presence of substance misuse,
or family choice, contraindicates dexamfetamine,
then Strattera should be considered. Grade B evidence
suggests that methylphenidate non-responders have
around a 40% chance of responding to Strattera [43].
Which extended-release preparation of
methylphenidate?
Clinical practice will often begin with a decision about
profile of effect desired across the day. Loss of control
in the evenings or preference for evening control by
the family will indicate the longer acting; insomnia
may suggest the shorter-acting one. The smaller initial
effect of Concerta XL may mean that morning control
is achieved at the price of greater overall exposure to
methylphenidate compared to Equasym XL, Ritalin
LA or Medikinet Retard. Where this is an issue (e.g.,
for the family) then Equasym XL, Ritalin LA or
Medikinet Retard would be preferred. An alternative
strategy would be to combine Concerta XL with a
morning dose of immediate release (see below). There
is, however, a range of individual variation. Equasym
XL is somewhat more expensive (at the time of writ-
ing) but has the property, along with Medikinet Re-
tard and Ritalin LA, that the capsules can be opened
and the contents sprinkled on food. This helps some
children who have difficulty swallowing; but the
opportunity to administer it surreptitiously should
not be taken because of the potentially harmful effects
of stealth on trust.
Should combination of treatments be used?
Extended-release preparations were designed to give a
good profile of action across the day. Nevertheless,
the range of individual variation suggests that some
children on extended-release formulations may be
helped by an additional dose of immediate-release
(beginning with 5 mg); either in the morning to assist
with control at the beginning of the day; or in the
evening to prevent an unsettling loss of action (which
may manifest either in disruptive behaviour or in
initial insomnia).
j Other considerations
Comorbidity
Little evidence exists of the specific advantages or
disadvantages of short-acting versus long-acting
treatments in relation comorbidities. In general, more
3However, the IR MPH overcoat of the capsule could still be mis-
used.
4Since these are determined by price, and price will vary from time
to time and place to place, the prescriber is advised to check these
generalisations against current circumstances. When considering
the total medication costs there is more than just the cost of one pill
to consider. Many patients taking one medication require longer
coverage, top-up doses and medication for comorbidities or side
effects. One should not choose a long-acting medication purely
based on price.
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RCT data is available for Strattera than other formu-
lations.
Tics: Methylphenidate is not necessarily contrain-
dicated in people with tics although in individual
cases it can be a hazard [47, 72]. Responsive discus-
sion with the family is useful to determine the utilities
they attach to tic severity against severity of ADHD.
In the case of treatment-emergent tics or comorbid
tics Strattera is a useful alternative and does not
worsen tics and may even improve them [2].
Anxiety: Patients with ADHD and comorbid anxi-
ety or disruptive behaviour disorders have as robust a
response of their ADHD symptoms to stimulants as
do patients who do not have these comorbid condi-
tions [45]. A 12-week double-blind, placebo-con-
trolled trial [67] found that Strattera significantly
reduced symptoms of both ADHD and anxiety rela-
tive to placebo, showing the drug to be efficacious in
the treatment of both conditions with a moderate
effect size (0.5) for anxiety.
Oppositional defiant disorder: A meta-analysis of
28 studies found that stimulant effects for aggression-
related behaviours in ADHD had effect sizes similar to
those for the core symptoms of ADHD but these ef-
fects were smaller for patients diagnosed with conduct
disorder [9]. Extended release methylphenidate for-
mulations [63, 74, 80], Adderall XR [62] and Strattera
[25, 46] have been shown to be effective at treating
comorbid cases. Data for Strattera are conflicting with
regard to effects on symptoms of ODD themselves,
with an effect-size of 0.39 in the US-study [46] and a
lack of significance in a European study [3].
Depression: Preliminary data suggest no effect of
Strattera on depression (unlike stimulants for which
it is a recognised though uncommon complication).
Strattera should not be regarded as an anti-depres-
sant.
Autism or mental retardation: Both stimulants and
Risperidone can be superior to placebo in treating
hyperactivity/impulsivity when it occurs in people
with Autism or mental retardation. Risperidone has
not been considered elsewhere in these guidelines, as
it is not approved generally for the treatment of
ADHD, but it may well be considered if autism is
present too. Pending further research, these combi-
nations of symptoms are not a specific indication for
either ER stimulants or Strattera. Due to the potential
for increased side effects cautious dosing for these
combinations of symptoms is required.
ADHD across the lifespan
Pre-school ADHD: The diagnosis of pre-school
ADHD is deemed problematic by many clinicians
but can be made reliable [58]. This is despite per-
sisting concerns over the difficulty of distinguishing
ADHD from normal developmental variations in
activity and attention [59]. Given concerns about
the lack of evidence relating to the long-term effects
of very early initiated extended MPH treatment,
drugs should be prescribed very cautiously and
evidence-based psychological approaches (such as
structured parent training) should normally take
precedence in the first instance. Evidence with re-
gard to the efficacy of short acting MPH formula-
tions was described in the revised European
guidelines [71]. While MPH can be efficacious for
pre-schoolers, RCT evidence is sparse and where
available effects on core symptoms were generally
smaller and side effects more pronounced than for
older children [22, 33]. There is currently no evi-
dence, (and no evidence was submitted to the
Guidelines group) specifically in relation to the
efficacy of effectiveness of long-acting stimulant or
non-stimulant drug formulations in pre-school
ADHD.
Adult ADHD: ADHD often persists beyond the
adolescent years, with the majority of cases dis-
playing either the operationally defined disorder or
the persistence of some symptoms associated with
significant levels of academic, occupational and so-
cial impairment and a high level of psychiatric
comorbidity [5, 13, 16, 19, 50]. Clinical experience
suggests that there is a significant subset of indi-
viduals who benefit greatly from the appropriate use
of stimulants and other drug treatments, but data
do not allow accurate estimation of the proportion
of individuals with ADHD who require long-term
medical treatment. At the time of writing, most
drug treatments are not licensed for use within the
adult population in any European country. This
means that current prescriptions are written ‘off-
label’. The exception is Strattera, which is licensed
for use in adults but only when treatment was
initiated in childhood or adolescence. Nevertheless,
the guidelines group conclude that both stimulants
and Strattera are effective in adults with ADHD and
recommend their clinical use, both for individuals
who started treatment in childhood/adolescence, as
well as for individuals receiving a first time diag-
nosis of ADHD in adulthood.
In most cases, lack of licensing in the adult
population has not come about from failed licensing
applications, but rather from a historical lack of
interest of treating ADHD in adults from both cli-
nicians and drug companies. It is envisaged that
this situation will change in the near future since
several of the ER preparations are undergoing
European trials in adult ADHD samples to dem-
onstrate the safety and efficacy levels required by
the licensing agencies. The treatment of adults is
likely to remain a specialist interest in the short-
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term, although in the medium term an increasing
number of adult psychiatrists and adult mental
health services are expected to incorporate treat-
ment of ADHD into their general practice.
The short-term effectiveness of stimulants in adult
life has been demonstrated with meta-analysis of
available data showing similar effect sizes to that seen
in child and adolescent samples [17]. They concluded
that the degree of efficacy of MPH, in treating adults
with ADHD, was similar to that reported from meta-
analyses of the child and adolescent literature, pro-
viding assurance for clinicians that the diagnosis and
treatment of ADHD can be validly applied in adult-
hood. The one area where different parameters may
operate is dosage level. Titration to an effective dose is
important [17]. The most common dose range used in
European adult ADHD clinics for IR methylphenidate
is 10–20 mg taken 3–5 times daily, with both higher
and lower dosing required in individual cases. Our
suggested maximum is 30 mg for each dose. The use of
extended release stimulants has been less extensively
investigated in the adult ADHD population but the
similarity in treatment effect sizes for IR MPH sug-
gests that the guidelines for their use in older children
and adolescents should be followed for adults. As with
IR preparations titration to a clinically effective dose is
required. One large trial of Concerta XL [6] involved a
randomised, 6-week, placebo-controlled, parallel de-
sign study of Concerta XL in 103 adult patients with
DSM-IV ADHD. Dosage could be titrated up to
1.3 mg/kg/day; the average daily dose used in this
study was 72 mg, and the maximum 108 mg/day.
For an adult with a long working day and
responsibilities in the evening, or where marked
behavioural symptoms such as irritability and
impulsivity appear once the effects of medication
wear off alternative treatment may be needed.
Careful consideration of the timing of reappearance
of symptoms and the PK profile of each drug
should be considered in deciding whether to opt for
a supplement of IR medication or a change to
Strattera (see below). Similar treatment effect sizes
to those seen in children have also been shown
within available drug trials of Strattera [1, 44, 56].
As in children the possible advantages include re-
duced potential for drug misuse, extended action
throughout the day and a different profile of side
effects and hazards. The usual daily dose for adults
is 100 mg taken once per day. The same arguments
for and against the use of extended release prepa-
rations in children and adolescents also apply to
adults. The main difference here is the way that the
treatment options are evaluated since adult patients
are often capable of providing detailed descriptions
of their personal preferences. The main indications
for choosing ER preparations include compliance
issues, stigma or inconvenience in the work setting,
individual differences in response to drugs with
different PK profiles, and concern over potential
drug misuse. Depending on the profile of symptoms
and associated impairments, individuals often ex-
press preferences—either for drugs that have sus-
tained effects, such as Strattera or ER preparations,
or for IR preparations, which provide flexibility for
some individuals who do not require or desire
treatment all the time. Some individuals have
trouble with the on-off effects of IR drugs and
prefer the ‘smoother’ effects of ER preparations.
Others have no trouble regulating their use of IR
medication and prefer the added control that use of
IR preparations gives them for dose and timing of
dose throughout the day. The choice of drugs with
different PK profiles increases the chances of find-
ing one that is suited to an individual patient’s
symptom profile and individual clinical require-
ments.
A quantitative comparison of long-acting
treatments
j Pharmacokinetics
Laboratory studies suggest a close relationship be-
tween PK and pharmacodynamic (PD) properties;
PD studies of both IR & ER stimulants suggest that
the PD profiles closely mirrors both the IR & ER
PK profiles. Thus, methylphenidate plasma levels of
different ER-stimulant preparations measured over
time across the day correspond to their profile of
efficacy [21]. Clinical superiority at any point in
time is typically achieved by the formulation with
the highest expected plasma MPH concentration
[60, 70]. Thus, when given in roughly equivalent
daily doses the relative efficacy of preparations with
different dose delivery and PK profiles will vary
depending on the time since dosing. For example,
Equasym XL was found to be more effective than
Concerta XL early in day and vice versa late in day
[60, 70]. Figure 1 illustrates the typical plasma level
profiles for stimulants considered in this review
over time as a function of each formulations rela-
tive IR and ER proportions. Bioavailability curves
for MPH IR BID and Medikinet retard were pro-
vided by Medice and for Adderall XR by Shire; the
curve for Ritalin LA is based upon Markowitz et al.
[39]; curves for Concerta XL and Equasym XL are
based upon Gonzalez et al. [21]. All bioavailability
curves were adapted to a common time scale (X-
axis: hours) by the authors and serve as a com-
parison of the relative bioavailability of the for-
mulations over time, but direct comparisons
486 European Child & Adolescent Psychiatry (2006) Vol. 15, No. 8
 Steinkopff Verlag 2006
between the different preparations should not be
made for absolute plasma levels (Y-axis) as these
levels are dose-dependent. Moreover, it should be
noted that PK profiles may show considerable inter-
individual variation [29]. Caution should be ob-
served when generalising from these aggregated
profiles to individual patient cases.
Whilst these different delivery profiles do not dis-
tinguish any one preparation as ‘‘better’’ than the
other, they do provide the clinician with increased
options when choosing which preparation to use for a
particular patient. They also allow clinicians to pro-
vide a more flexible and sensitive individualised
adjustment whilst retaining the benefits of an ER
preparation. In much the same way as it is possible to
adjust individual doses of IR MPH to ensure that
symptoms are adequately treated across the day, it is
now also possible to choose an ER preparation whose
PK, and thus PD, profile, matches the patients’ needs
and preferences.
j Review methodology: rationale and procedure
Ideally, estimates of the relative efficacy of the different
long-acting formulations would be based upon pub-
lished high quality head-to-head comparisons. How-
ever, such direct comparative studies are largely
lacking and those available rarely allow to firm con-
clusions about the comparative efficacy of the products
to be drawn (e.g., because of exclusion of prior MPH-
responders or too short study duration). Therefore, the
group decided to compare the various efficacy mea-
sures of the different available products across studies,
by using a common set of standard efficacy indices:
treatment effect sizes (a measure of change) and
numbers needed to treat (a measure of outcome) (see
below). A working group (TB, DC, SP, AZ) made a
systematic review of published clinical trial literature
for the extended release preparations and unpublished
clinical trial data provided by the companies. The re-
viewonly included randomised, double-blind, placebo-
controlled studies not excluding medication non-re-
sponder a priori and presenting the means and stan-
dard deviations of either change scores or endpoint
scores for both medication and placebo groups.
j A comparison of treatment effect sizes
The calculation of effect sizes standardises the magni-
tude of the difference between outcomes in drug and
placebo groups so that a 1-point difference indicates
that the active treatment and placebo groups differ by 1
standard deviation on a particular outcome measure.
This allows a direct comparison of treatment effec-
tiveness across studies. A commonly used effect size
index is the standardised mean difference (SMD)—the
difference in outcome scores between drug and placebo
groups divided by the pooled standard deviation (of the
placebo and medication group at end of treatment).
Ideally, different medications should be compared by
calculating the SMDs based on the same outcome score
and the same type of rater for each medication. How-
ever, study design parameters, outcome measures and
the type of rater often varied among the double-blind,
placebo-controlled studies identified for review. Com-
paring effect sizes between studies is questionable if the
studies differ substantially in design features thatmight
influence medication versus placebo differences (e.g.,
Table 2 Mean medication effect sizes (SMDs) on total ADHD symptoms by preparation and type of rater
Parent Teacher Clinician
Total ADHD
SMD Number of
studies (rating
scales used)
SMD Number of
studies (rating
scales used)
SMD Number of
studies (rating
scales used) References
Adderall XR 0.9a* 1 1.1b* 1 1.2c** 1 Data on file Shire
Concerta XL 1.0d 1 1.0d 1 Wolraich et al. [80]
Equasym XL 0.6f 2 0.9d,f 1 1.8e*** 1 Greenhill et al. [23],
Swanson et al. [70],
Findling et al. [18]
Medikinet retard 1.0g 1 1.0g 1 0.9e,c*** 1 Do¨pfner et al. [10, 11]
Ritalin LA 1.0h 1 Biederman et al. [7]
ATX 0.7i 6 0.7c 11 Data on file Eli Lilly
Modafinil 0.6c 3 0.7c 3 Data on file Cephalon
Rating Scales: a Conners’ Global Index Scale-Parent Version (CGIS-P) (10 item);
b Conners’ Global Index Scale-Teacher Version (CGIS-T)(10 item); c ADHD-Rating
Scale; d Inattention/Overactivity with Aggression (IOWA) Conners Scale;
e Swanson, Kotkin, Alger, M-Flynn and Pelham (SKAMP) Scale; f Swanson, Nolan
And Pelham (SNAP) IV Questionnaire; g Fremdbeurteilungsbogen-HKS (German
version of the ADHD-Rating Scale); h Conners’ ADHD/DSM-IV Scale—Teacher
Version (CADS-T) (27 item); i Revised Conners’ Parent Rating Scale (27 item)
*Only children studied
**Only adolescents studied; a non-linear dose-response relationship between
dose and response was observed (20 mg: 1.2, 30 mg: 0.9, 40 mg: 0.9)
***Lab-school study
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different types of rater, durations of studies, dosing
regimens). Therefore, SMDs for the various ER medi-
cations were calculated separately for different types of
rater (parent, teacher, and clinician) and for the fol-
lowing outcome measures: total ADHD symptoms,
inattentive symptoms, and hyperactive/impulsive
symptoms. This approach was designed to help control
for potentially confounding factors across studies.
If a study presented data on more than one fixed
dose, the most efficient dose (which was usually the
highest dose) to reduce total ADHD symptoms was
used for the calculation of SMDs. As an exception,
a non-linear dose-response relationship between
dose and response (SMD) was observed for Adderall
XR efficacy in the clinicians’ ratings of total ADHD
adolescents (20 mg: 1.2, 30 mg: 0.9, 40 mg: 0.9).
Where there was more than one study dataset
available, SMDs were averaged to a corresponding
overall SMD. Averaging was done by weighting the
single studies’ SMDs by the corresponding numbers
of subjects included in the study. Company calcu-
lations using a standard approach were employed
for Medikinet Retard, Strattera, Adderall XR, Mod-
afinil. The authors calculated the SMDs for Concerta
XL based upon the results of a randomised, double-
blind placebo-controlled study from a published
paper [80]; two other randomised, double-blind
placebo-controlled studies on Concerta XL were
identified by the systematic review [48, 69]; these
included MPH-responders exclusively (i.e., children
who previously had a prior poor response to MPH
were excluded) and their SMDs were substantially
higher than those of studies investigating unselected
samples. In order to ensure comparability, results
Table 3 Mean medication effect sizes (SMDs) on inattention symptoms by preparation and type of rater (n = number of studies)
Parent Teacher Clinician
Inattention
SMD Number of
studies (rating
scales used)
SMD Number of
studies (rating
scales used)
SMD Number of
studies (rating
scales used) References
Adderall XR 1.2a* 1 Data on file Shire
Concerta XL No data available
Equasym XL 0.7d 2 0.8b,d 1 Greenhill et al. [23],
Swanson et al. [70],
Findling et al. [18]
Medikinet retard 1.0e 1 1.1e 1 0.8c** 1 Do¨pfner et al. [10, 11]
Ritalin LA 0.9f 1 Biederman et al. [7]
ATX 0.6a 10 Data on file Eli Lilly
Modafinil 0.6a 3 0.6a 3 Data on file Cephalon
Rating Scales: a ADHD-Rating Scale; b Inattention/Overactivity with
Aggression (IOWA) Conners Scale; c Swanson, Kotkin, Alger, M-Flynn and Pel-
ham (SKAMP) Scale; d Swanson, Nolan And Pelham (SNAP) IV Questionnaire;
e Fremdbeurteilungsbogen-HKS (German version of the ADHD-Rating Scale);
f Conners’ ADHD/DSM-IV Scale—Teacher Version (CADS-T) (27 item)
*Only adolescents studied; SMD at 40 mg was 1.8
**Lab-school study
Table 4 Mean medication effect sizes (SMDs) on hyperactivity/impulsivity symptoms by preparation and type of rater (n = number of studies)
Parent Teacher Clinician
Hyperactivity/Impulsivity
SMD Number of studies
(rating scales used)
SMD Number of studies
(rating scales used)
SMD Number of studies
(rating scales used) References
Adderall XR 1.1a* 1 Data on file Shire
Concerta XL No data available
Equasym XL 0.6d 2 0.9b,d 1 Greenhill et al. [23],
Swanson et al. [70],
Findling et al. [18]
Medikinet retard 1.0e 1 1.1e 1 0.7c** 1 Do¨pfner et al. [10, 11]
Ritalin LA 0.9f 1 Biederman et al. [7]
ATX 0.6a 10 Data on file Eli Lilly
Modafinil 0.5a 3 0.6a 3 Data on file Cephalon
Rating Scales: a ADHD-Rating Scale; b Inattention/Overactivity with Aggression
(IOWA) Conners Scale; c Swanson, Kotkin, Alger, M-Flynn and Pelham (SKAMP)
Scale; d Swanson, Nolan And Pelham (SNAP) IV Questionnaire; e Fre-
mdbeurteilungsbogen-HKS (German version of the ADHD-Rating Scale);
f Conners’ ADHD/DSM-IV Scale—Teacher Version (CADS-T) (27 item)
*Only adolescents studied
**Lab-school study
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from these studies were not considered for the
calculation of the SMDs for Concerta XL. SMD
calculations for Equasym XL are based upon
randomised placebo controlled studies provided by
UCB [18, 23, 70].
Tables 2–4 give mean effect sizes (SMDs) for each
preparation by the type of rater on ADHD symptom
domains and the numbers of studies and rating scales
(indexed) onwhich these figures are based upon.While
the various long-acting stimulants differ according to
their PK and PD profiles (see above), their SMDs are
strikingly similar and comparable to the figures re-
ported across raters for this class of medication in the
recent meta-analysis; no significant difference in effect
size was observed for immediate-release stimulants
compared with long-acting stimulants [14, 15]. SMDs
of immediate release methylphenidate on core symp-
toms of ADHD in children from randomised, double-
blind, placebo-controlled trials are between 0.8 to 1 [14,
15, 30]; SMDs vary among symptom domains, with the
strongest effects of stimulant medication on measures
of attention, distractibility, and impulsivity and ob-
servable social and classroom behaviour. For adult
ADHD, Faraone et al. [17] calculated a mean SMD of
0.9 based on six trials including a total of 140 MPH-
treated ADHD adults and 113 placebo-treated ADHD
adults. When treatment was optimised to high doses,
the SMD for MPH in adults was 1.3.
Overall, our results support conclusions of the re-
cent meta-analysis that long-acting stimulants have
similar SMDs to immediate-release stimulants (evi-
dence level Ia) while SMDs for non-stimulants are
somewhat smaller [14, 15] Although it should be
borne in mind that effect sizes cannot provide
definitive guidelines for clinical practice, they do
provide additional information for clinicians to con-
sider when planning treatment regimens for ADHD
patients [12, 14, 15]. Limitations of these data include
the inability to control for the effects of potential
confounding variables (differences concerning the
distribution of diagnostic subtypes, gender, and age,
design of study (parallel versus crossover; lab-school
versus naturalistic setting), type of outcome score
used (change score versus endpoint score), source of
information of the clinicians’ rating,5 dosing method
(fixed dose versus best dose), and use of placebo lead-
in (yes/no).
j A comparison of normalisation rates and numbers
needed to treat
Normalisation rates are defined as the proportion of
patients normalised, e.g., having no problems more
than ‘‘mild’’ (i.e. Conners scale T-score < 63 or
SNAP < 1/item). Once again these were provided by
the companies, except for Concerta XL, for which no
formal ‘‘Normalisation’’ analysis had been completed.
The only published paper reporting normalisation
data was Stein et al. [66], which was not an adequate
double-blind study (appearance of placebo and OROS
different). Thus, these figures cannot be compared to
those of the other preparations. From these normal-
isation data, Number Needed to Treat (NNT) can be
calculated (see below). The NNT corresponds to the
expected number of patients needed to be treated to
see one patient normalise in terms of ADHD symp-
toms with medication and would not have normalised
on placebo therapy. This is a common treatment
efficacy outcome measure in contrast to SMD, which
is a measure of change by treatment. NNT is com-
puted as follows:
NNT ¼ 1=ðPercent improved on Drug
 Percent improved on Placebo 100Þ
Confidence intervals (CI) for NNT are calculated as
follows:
CI ¼ 1.96Square root½fðnormalisation rate*ð1
 normalisation rate))/n placebog
þ fðnormalisation rate*(1
 normalisation rate))n treated groupg]
Whilst comparisons are somewhat limited by the use
of different measures and slightly different definitions
of normalisation (e.g., SNAP scores £ 1/item versus
ADHS-RS £ T-score 63), figures suggest that differ-
ences between the ER medications investigated are
smaller using this metric than using the SMD analysis.
An exception is the data for Concerta XL. However,
these normalisation data may be inflated because of
an inadequate study design [66]6 and results should
therefore not be compared directly to the other
products’ figures straightforward. The relative efficacy
for Strattera using this index also seems stronger. One
possible explanation for the discrepancy between
measures may relate to a relatively larger efficacy of
5It has to be mentioned that clinician ratings were based on dif-
ferent sources of information. The Medikinet retard and Equasym
XL studies used direct observations (lab-school ratings). In the
Strattera trials, clinical investigators were specifically instructed not
to use any other information as the basis for the rating except
parent interviews (most Strattera studies), respectively teacher re-
ports (one Strattera study;75. Weiss M, Tannock R, Kratochvil C,
Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens
L, Allen AJ (2005) A randomised, placebo-controlled study of once-
daily ATX in the school setting in children with ADHD. J Am Acad
Child Adolesc Psychiatry 44:647–655).
6The appearance of placebo and Concerta XL was different, i.e. it
was not a blinded study.
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ER stimulants than Strattera on more severely im-
paired patients (which are not normalised by treat-
ment). This possibility needs to be investigated
further. (Table 5)
It is worth noting that the effect sizes and NNTs for
these medications compare favourably with those re-
ported for other psychiatric drugs. For example, the
effect sizes and NNT for antidepressants in the treat-
ment of adult depression or obsessive-compulsive
disorder are in the region of 0.5 and 9, respectively [20,
61]; and for atypical antipsychotics in the treatment of
schizophrenia are around 0.25 and 20 [35].
j Quality of life
Quality of Life measurement is a desirable part of
clinical trials, but has not often been applied suffi-
ciently frequently, or has been applied with too little
power [8]. Panels of parents have been asked to de-
velop utility measures for cost-effectiveness estimates,
but the method has not yet been able to give robust
comparisons of drugs [30]. A systematic review is
therefore not included in this paper. The Child Health
Questionnaire is sensitive to the psychosocial deficits
in ADHD [31] and was used to conclude that Strat-
tera is superior to placebo in random-allocation
double-blind trials (n = 747) [40, 49]. Open label
studies of Strattera with a total of 921 participants
[52] suggest an SMD of around 1.0 SD.—especially on
a psychosocial summary score, a family activities
subscale and a parent emotional impact subscale. The
QoL Enjoyment and Satisfaction Questionnaire (Q-
LES-Q) was used in a long-term open extension study
of Adderall XR; parents rated a 15% increase after
1 year on treatment [37]. A range of specific domains
of functioning that are likely to be related to QoL
have been used to show positive effects of extended-
release methylphenidate Concerta XL. These include
family functioning, parental stress, social interac-
tions, academic functioning/homework improvement
[48, 65, 69].
Recommendations for future study
The database remains rather limited for all issues
other than the comparison of drugs with placebo on
symptom rating scales. The effects on QoL or utility
ratings; the head-to-head comparisons between
drugs; efficacy in subtypes of ADHD (such as
hyperkinetic disorder and various comorbidities);
effectiveness studies in real-world settings; and
economic analyses such as cost-effectiveness; all
need development. Long-term safety assessments
are pressingly needed. Ta
b
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Summary and Conclusions
The above review has revealed that long-acting for-
mulations are effective in the management of ADHD
and are a useful addition to the clinical repertoire.
Although there is limited evidence, studies suggest
that ER stimulants are equivalent to multiple doses of
IR. While effect sizes are somewhat smaller for
Strattera than ER stimulants, numbers-needed-to-
treat are more similar and it is also to be considered
an effective treatment of ADHD. Time course for the
different formulations differ. Hazards differ for the
two classes of drugs. Abuse potential appears to be
low for all the drugs, with Strattera least likely and
dexamfetamine most likely licensed drugs to be abu-
sed—but more research, especially in relation to
adolescent diversion and misuse, is required. Treat-
ment in adulthood is appropriate but great caution is
required in relation to pre-school children. Costs vary
and cost-effectiveness calculations are not yet ade-
quate to guide practice.
More specifically it is recommended that
• Long-acting preparations should be available andused.
• They should not replace short-acting drugs (which
will be the initial treatment for many children for
reasons of cost and flexibility of dosing). Individual
clinical choice is needed.
• Both ATX (Strattera) and extended-release prepa-
rations of stimulants should be available. The
choice will depend upon the circumstances:
• If treatment is starting with a long-acting prepara-
tion, then start with extended-release methylphe-
nidate and proceed to Strattera if the former is
unhelpful. The choice of extended-release methyl-
phenidate will depend upon the profile of action
required over time, and upon the availability of
drug. Strattera may nevertheless be preferred as
first choice if substance abuse or comorbid tics are
a problem, if there is a strong family preference for
a non-stimulant, if a 24-h action is particularly
strongly required or if there is comorbid anxiety.
• If a child has responded well to an immediate-re-
lease stimulant, there may still be reasons to shift to
extended-release—for example, to avoid the stigma
or inconvenience of repeated dosing. An extended-
release preparation of methylphenidate will then be
preferred.
• If a child has suffered adverse effects on immediate-
release methylphenidate, then the next step will
often be to proceed to Strattera.
• If a child has failed to respond to immediate-release
methylphenidate, because of lack of efficacy rather
than adverse effect, then the next option is to try
dexamfetamine or Strattera depending on the rel-
ative balance of advantages.
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Appendix 1
Excerpts from: ‘‘SIGN 50: A guideline developers’
handbook Section 6: Forming guideline recommen-
dations’’ [55]
These excerpts are included to assist the reader
understand the grading system used in this guideline.
They are not intended as a substitute for the full SIGN
guidance and anyone wishing to explore this area
further should consult the full guidance [55]:
‘‘Guideline recommendations are graded to dif-
ferentiate between those based on strong evidence
and those based on weak evidence. This judgment is
made on the basis of an (objective) assessment of the
design and quality of each study and a (perhaps more
subjective) judgment on the consistency, clinical rel-
evance and external validity of the whole body of
evidence. The aim is to produce a recommendation
that is evidence-based, but which is relevant to the
way in which health care is delivered and is therefore
implementable.
It is important to emphasise that the grading does
not relate to the importance of the recommendation,
but to the strength of the supporting evidence and, in
particular, to the predictive power of the study de-
signs from which that data was obtained. Thus, the
grading assigned to a recommendation indicates to
users the likelihood that, if that recommendation is
implemented, the predicted outcome will be
achieved.’’ SIGN grading system
Levels of evidence
1++ High quality meta analyses, systematic reviews of
RCTs, or RCTs with a very low risk of bias
1+ Well conducted meta analyses, systematic reviews of
RCTs, or RCTs with a low risk of bias
1) Meta analyses, systematic reviews of RCTs, or RCTs with
a high risk of bias
2++ High quality systematic reviews of case-control or
cohort studies, High quality case–control or cohort
studies with a very low risk
of confounding, bias, or chance and a high probability
that the relationship is causal
2+ Well conducted case–control or cohort studies with a low
risk of confounding, bias, or chance and a moderate
probability that
the relationship is causal
2) Case–control or cohort studies with a high risk of
confounding, bias, or chance and a significant risk that
the relationship is not causal
3 Non-analytic studies, e.g. case reports, case series
4 Expert opinion
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On occasion, guideline development groups find
that there is an important practical point that they
wish to emphasise but for which there is not, nor is
their likely to be, any research evidence. This will
typically be where some aspect of treatment is re-
garded as such sound clinical practice that nobody is
likely to question it. These are marked in the guide-
line as Good Practice Points, and are indicated . It
must be emphasised that these are not an alternative
to evidence-based recommendations, and should only
be used where there is no alternative means of high-
lighting the issue.
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Grades of recommendation
A At least one meta-analysis, systematic review, or RCT rated as 1++,
and directly applicable to the target population; or
A systematic review of RCTs or a body of evidence consisting
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population, and demonstrating overall consistency of results
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